Regeneron Pharmaceuticals (NASDAQ:REGN) Stock: Insider Andrew Murphy Sells 4,147 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider Andrew Murphy sold 4,147 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Stock Down 0.7%

Shares of REGN opened at $790.74 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $566.11 and a 52 week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The firm has a market cap of $81.41 billion, a P/E ratio of 20.44, a price-to-earnings-growth ratio of 1.38 and a beta of 0.16. The firm’s 50-day simple moving average is $791.72 and its 200 day simple moving average is $721.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The company’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $12.81 EPS. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on REGN shares. Raymond James Financial raised their price objective on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Truist Financial boosted their target price on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Jefferies Financial Group upped their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, Robert W. Baird lifted their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $845.21.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in REGN. BlackRock Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. State Street Corp increased its stake in Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after buying an additional 170,210 shares during the period. Invesco Ltd. boosted its holdings in Regeneron Pharmaceuticals by 7.2% in the fourth quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock valued at $1,228,127,000 after purchasing an additional 106,632 shares during the period. Bank of America Corp DE grew its position in shares of Regeneron Pharmaceuticals by 8.5% during the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock worth $805,023,000 after buying an additional 101,469 shares in the last quarter. Finally, Amundi lifted its holdings in Regeneron Pharmaceuticals by 0.4% during the 2nd quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after buying an additional 3,742 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly performance supported the bullish case. Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above analyst expectations. Earnings per share of $14.29 also exceeded the $10.16 consensus estimate, reinforcing confidence in the company’s earnings momentum. Regeneron earnings and investment narrative
• Positive Sentiment: Positive 84-week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva indicated a sustained reduction in new heterotopic bone lesions and disease flare-ups, with a generally consistent safety profile. The results could strengthen confidence in the treatment’s commercial opportunity. Regeneron OPTIMA trial results
• Positive Sentiment: UBS upgraded REGN to Buy and raised its price target to $978 from $660, citing greater long-term potential for Dupixent and arguing that the market may be undervaluing the business. UBS Regeneron upgrade
• Positive Sentiment: Libtayo received a positive recommendation from the European Medicines Agency’s CHMP for a dosing regimen that could reduce administration frequency from every three weeks to every six weeks after the first 12 weeks, potentially improving convenience and market appeal. Final EU approval is still required. Libtayo CHMP recommendation
• Negative Sentiment: Insider Andrew Murphy sold 4,147 shares worth approximately $3.2 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, limiting its significance, but it may contribute modestly to near-term caution. Regeneron insider sale filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.